Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Artgen Biotech PJSC's share price for the quarter that ended in Jun. 2023 was ₽104.02. Artgen Biotech PJSC's Shares Outstanding (EOP) for the quarter that ended in Jun. 2023 was 74 Mil. Therefore, Artgen Biotech PJSC's market cap for the quarter that ended in Jun. 2023 was ₽7,721 Mil.
Artgen Biotech PJSC's quarterly market cap
increased
from Jun. 2022 (₽4,247 Mil) to Dec. 2022 (₽5,065 Mil) and
increased
from Dec. 2022 (₽5,065 Mil) to Jun. 2023 (₽7,721 Mil).
Artgen Biotech PJSC's annual market cap
increased
from Dec. 2020 (₽2,862 Mil) to Dec. 2021 (₽8,433 Mil) but then
declined
from Dec. 2021 (₽8,433 Mil) to Dec. 2022 (₽5,065 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Artgen Biotech PJSC's Enterprise Value for Today is ₽6,192 Mil.
Artgen Biotech PJSC (MIC:ABIO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Artgen Biotech PJSC Market Cap Related Terms
Artgen Biotech PJSC Market Cap Historical Data
* Premium members only.
The historical data trend for Artgen Biotech PJSC's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIC:ABIO vs VRTX, REGN, SGEN: Market Cap Comparison
For the Biotechnology subindustry, Artgen Biotech PJSC's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artgen Biotech PJSC Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artgen Biotech PJSC's Market Cap distribution charts can be found below:
* The bar in red indicates where Artgen Biotech PJSC's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Artgen Biotech PJSC's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artgen Biotech PJSC (MIC:ABIO) has a Market Cap of ₽4,072 Mil as of Aug. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Artgen Biotech PJSC and its competitors.
Is Artgen Biotech PJSC's Market Cap too high?
Artgen Biotech PJSC's current Market Cap is ₽4,072 Mil. Overall, Artgen Biotech PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Artgen Biotech PJSC's Market Cap compare to VRTX and REGN?
Artgen Biotech PJSC's Market Cap of ₽4,072 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 122.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 122.85, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Artgen Biotech PJSC and its competitors. For the Biotechnology industry, the median Market Cap is 122.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artgen Biotech PJSC's current Market Cap is ₽4,072 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artgen Biotech PJSC stock overvalued right now?
Artgen Biotech PJSC (MIC:ABIO) has a current Market Cap of ₽4,072 Mil. The current Market Cap is ₽4,072 Mil. Artgen Biotech PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Artgen Biotech PJSC (MIC:ABIO), the current Market Cap is ₽4,072 Mil as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artgen Biotech PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
17GF Score
Get the complete analysis for MIC:ABIO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIC:ABIO has been successfully added to your 
